ADCs (Antibody Drug Conjugates) are among the fastest growing drug classes in oncology and are being explored in autoimmune diseases. In principle, these therapeutic entities are designed to widen the therapeutic window of the linked drugs by limiting their delivery specifical to cells that express the target antigen of the selected mAb. Progress in synthetic biochemistry methods, linker technology and novel payload discovery, has paved the way for DualityBio to build the new generation of ADCs with the potential to improve upon the activity and toxicity profiles of earlier generations of ADCs.
With deep insights into the disease biology and pharmacology, DualityBio generates novel modality assets through internal and external innovation to address the unmet medical needs. The therapeutic potential of the new modalities is maximized through DualityBio’s proprietary drug engineering platforms and translational platforms to generate therapeutic candidates with highest possible chance of success in terms of both safety and efficacy. The candidates are developed through an agile model (e.g. internal development, external partnership) to ensure fast progression to clinics for proof of concept.
Duality Novel Platforms contain a series of proprietary linker-payload libraries, which can be applied to multiple areas including oncology and autoimmune diseases. The linker-payloads and conjugated drugs were rationally designed and selected for the desired physicochemical properties, biological activities and DMPK properties to achieve optimal safety and efficacy profile. The platforms can be readily expanded to various targeting moieties, including antibodies, proteins, peptides and small molecules, providing a fast and effective approach to develop potential best-in-class and/or first-in-class drug candidates for the unmet medical needs.